|
|
|
|
| LEADER |
02104nmm a2200277 u 4500 |
| 001 |
EB001800638 |
| 003 |
EBX01000000000000000974136 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
180405 ||| eng |
| 020 |
|
|
|a 9783319679327
|
| 100 |
1 |
|
|a Yarden, Yosef
|e [editor]
|
| 245 |
0 |
0 |
|a Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
|h Elektronische Ressource
|c edited by Yosef Yarden, Moshe Elkabets
|
| 250 |
|
|
|a 1st ed. 2018
|
| 260 |
|
|
|a Cham
|b Springer International Publishing
|c 2018, 2018
|
| 300 |
|
|
|a XX, 242 p. 22 illus. in color
|b online resource
|
| 505 |
0 |
|
|a Resistance of colorectal tumors to anti-EGFR antibodies -- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK -- Mechanisms of action and resistance of trastuzumab in breast cancer -- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis -- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge -- Mechanisms of resistance to PI3K and AKT inhibitors -- Sensitivity and resistance to BH3 mimetics in cancer therapy -- Resistance mechanisms to cyclin-dependent kinase inhibitors -- Resistance to inhibitors of angiogenesis
|
| 653 |
|
|
|a Cancer research
|
| 653 |
|
|
|a Cancer Research
|
| 700 |
1 |
|
|a Elkabets, Moshe
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a Resistance to Targeted Anti-Cancer Therapeutics
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-319-67932-7?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 614.5999
|
| 520 |
|
|
|a This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance
|